Shayan Cheraghlou, Mary L Stevenson, Sean R Christensen, Jeremy S Bordeaux, Joanna L Walker, Divya Srivastava, Carla Ferrándiz-Pulido, Kristin P Bibee, Joi B Carter, Faramarz H Samie, Vishal A Patel, Bryan T Carroll, Allison T Vidimos, Christian L Baum, Justin J Leitenberger, Anokhi Jambusaria-Pahlajani, Emily S Ruiz, John A Carucci, David R Carr, Kathryn T Shahwan
IMPORTANCE: Cutaneous squamous cell carcinoma (CSCC) is the second most common malignant disease in the US. Although it typically carries a good prognosis, a subset of CSCCs are highly aggressive, carrying regional and distant metastatic potential. Due to its high incidence, this aggressive subset is responsible for considerable mortality, with an overall annual mortality estimated to equal or even surpass melanoma. Despite this morbidity, CSCC is excluded from national cancer registries, making it difficult to study its epidemiology and outcomes...
July 24, 2024: JAMA Dermatology
Alyssa Susanto, Vaishnavi Nathan, Monika Janda, Kiarash Khosrotehrani, Erin McMeniman, H Peter Soyer, Brigid Betz-Stablein
No abstract text is available yet for this article.
July 24, 2024: Australasian Journal of Dermatology
Elisabetta Maffei, Antonio D'Antonio, Maria Addesso, Savio Domenico Pandolfo, Paolo Verze, Alessandro Caputo
Melanomas originating within the urinary tract represent a rare and clinically challenging subset of malignancies. Despite extensive research on cutaneous melanomas, urinary tract melanomas remain relatively unexplored, presenting diagnostic dilemmas and limited treatment consensus. In this comprehensive review, we synthesize current knowledge on the epidemiology, risk factors, clinical presentation, histopathological characteristics, and treatment strategies specific to this disease. Enhancing clinical awareness, refining diagnostic approaches, and exploring novel therapeutic interventions hold promise for improving outcomes in this challenging malignancy subset...
July 24, 2024: Urologia
I A J van Duin, M Schuiveling, L S Ter Maat, M Veta, M J M van Eijs, R J Verheijden, F W P J van den Berkmortel, M J Boers-Sonderen, G A P Hospers, M Labots, J W B de Groot, E Kapiteijn, D Piersma, G Vreugdenhil, H Westgeest, A M R Schrader, P J van Diest, W A M Blokx, K P M Suijkerbuijk
BACKGROUND: The predictive value of tumor-infiltrating lymphocytes (TILs) in immune-related adverse event (irAE) development remains unknown, although an association between tumor immunogenicity and irAEs has been suggested. We investigated the association between TIL abundance in pretreatment primary and metastasis specimens and the subsequent development of severe irAEs. PATIENTS AND METHODS: We retrospectively identified patients with advanced cutaneous melanoma who received first-line anti-programmed cell death protein 1 (PD-1) with or without anti-cytotoxic T-lymphocyte associated protein 4 (anti-CTLA-4) from 10 hospitals in the Netherlands...
December 2024: Immunooncol Technol
Siddhi N Paudel, Brian J Hutzen, Katherine E Miller, Elizabeth A R Garfinkle, Chun-Yu Chen, Pin-Yi Wang, Andrea M Glaspell, Mark A Currier, Emily M Ringwalt, Louis Boon, Elaine R Mardis, Mitchell S Cairo, Nancy Ratner, Rebecca D Dodd, Kevin A Cassady, Timothy P Cripe
INTRODUCTION: Malignant peripheral nerve sheath tumors (MPNST) pose a significant therapeutic challenge due to high recurrence rates after surgical resection and a largely ineffective response to traditional chemotherapy. An alternative treatment strategy is oncolytic viroimmunotherapy, which can elicit a durable and systemic antitumor immune response and is Food and Drug Administration (FDA)-approved for the treatment of melanoma. Unfortunately, only a subset of patients responds completely, underscoring the need to address barriers hindering viroimmunotherapy effectiveness...
2024: Frontiers in Immunology
Huiying Wan, Ling Zhong, Tian Xia, Dingding Zhang
BACKGROUND: Exosomes contain abundant circular RNAs (circRNAs), playing an important role in intercellular communication. However, the function and underlying molecular mechanism of exosomal circRNAs in foot metastatic melanoma remain unclear. METHODS: Twelve differentially expressed exosomal circRNAs between patients with metastatic and primary foot melanoma were screened through high-throughput sequencing, and their expression levels were detected by the real-time reverse transcriptase-polymerase chain reaction (RT-qPCR)...
2024: Cancer Management and Research
P Stephen Patrick, Daniel J Stuckey, Huachen Zhu, Tammy L Kalber, Haadi Iftikhar, Paul Southern, Joseph C Bear, Mark F Lythgoe, Simon R Hattersley, Quentin A Pankhurst
Magnetic field hyperthermia relies on the intra-tumoural delivery of magnetic nanoparticles by interstitial injection, followed by their heating on exposure to a remotely-applied alternating magnetic field (AMF). This offers a potential sole or adjuvant route to treating drug-resistant tumours for which no alternatives are currently available. However, two challenges in nanoparticle delivery currently hinder the effective clinical translation of this technology: obtaining enough magnetic material within the tumour to enable sufficient heating; and doing this accurately to limit or avoid damage to surrounding healthy tissue...
July 24, 2024: Nanoscale
Ana M García, Luis G Parra-Lara, Diana M Mendoza-Urbano, Juan C Bravo, Ángela Zambrano Harvey
BACKGROUND: Mucosa melanoma is a rare condition with aggressive behavior and a less favorable prognosis compared to cutaneous melanoma. The objective of this study was to estimate the overall survival and clinical outcomes of patients diagnosed with mucosal melanoma in a Colombian hospital. METHODS: A retrospective cohort study was conducted at Fundación Valle del Lili, a single center located in Cali, Colombia. Patients aged ≥ 18 years, both sexes, diagnosed with mucosal melanoma by histopathology study were included between 2010-2019...
July 23, 2024: BMC Cancer
Palak Sharma, Shreya Kaul, Neha Jain, Manisha Pandey, Upendra Nagaich
Skin carcinoma remains one of the most widespread forms of cancer, and its global impact continues to increase. Basal cell carcinoma, melanoma, and squamous cell carcinoma are three kinds of cutaneous carcinomas depending upon occurrence and severity. The invasive nature of skin cancer, the limited effectiveness of current therapy techniques, and constraints to efficient systems for drug delivery are difficulties linked with the treatment of skin carcinoma. In the present era, the delivery of drugs has found a new and exciting horizon in the realm of nanotechnology, which presents inventive solutions to the problems posed by traditional therapeutic procedures for skin cancer management...
July 24, 2024: AAPS PharmSciTech
Peizhe Yuan, Yu Long, Nannan Wei, Yan Wang, Ziyang Zhu, Jinquan Han, Dawei Jiang, Xiaoli Lan, Yongkang Gai
BACKGROUND: Lymphocyte activation gene 3 (LAG-3) is expressed on activated immune cells and has emerged as a promising target for immune checkpoints blockade. However, conflicting findings have been reported regarding the association between LAG-3 expression in tumors and patient prognosis, indicating the need for further investigation into the significance of LAG-3 expression levels in tumor therapies. In this study, 68 Ga-NOTA-XH05, a novel peptide-based positron emission tomography (PET) tracer targeting LAG-3, was constructed to non-invasively detect LAG-3 expression in melanoma after CpG oligonucleotide (CpG) treatment and explore the relationship between LAG-3 expression and therapeutic effect...
July 23, 2024: Journal for Immunotherapy of Cancer
Thu Ha Dang, Nilmini Wickramasinghe, Prem Prakash Jayaraman, Kate Burbury, Marliese Alexander, Ashley Whitechurch, Steve Quinn, Gail Rowan, Sally L Brooks, Penelope Schofield
INTRODUCTION: With the increasing use of oral anti-cancer medicines (OAMs), research demonstrating the magnitude of the medication non-adherence problem and its consequences on treatments' efficacy and toxicity is drawing more attention. Mobile phone interventions may be a practical solution to support patients taking OAMs at home, yet evidence to inform the efficacy of these interventions is lacking. The safety and adherence to medications and self-care advice in oncology (SAMSON) pilot randomised control trial (RCT) aims to evaluate the acceptability, feasibility and potential efficacy of a novel digital solution to improve medication adherence (MA) among people with cancer...
July 23, 2024: BMJ Open
Elisabetta Michielon, Alexandre C Motta, Jonas Ogien, Paul Oranje, Taco Waaijman, Varsha Thakoersing, Sanne Veldhorst, Tanja D de Gruijl, Susan Gibbs
BACKGROUND: In tissue engineering, real-time monitoring of tumors and of the dynamics of the microenvironment within in vitro models has traditionally been hindered by the need to harvest the cultures to obtain material to analyze. Line-field confocal optical coherence tomography (LC-OCT) has proven to be useful in evaluating in vivo skin conditions, including melanoma, by capturing dynamic, three-dimensional (3D) information without the need for invasive procedures, such as biopsies...
July 10, 2024: Journal of Dermatological Science
Joseph Elijah, Igor Puzanov, Benjamin Cresanti, Lamya Hamad, Kristopher Attwood, Kayla Catalfamo, Grazyna Riebandt
BACKGROUND: Real-world safety outcomes between the two flat-dose nivolumab regimens demonstrated to be similar in a study of adjuvant nivolumab recipients for melanoma. However, this study was limited by a single oncology patient population, a small sample size, and insufficient study power. The primary objective of this study was to evaluate the incidence of immunotherapy-related adverse effects (irAEs) between nivolumab regimens with differing dosing patterns in various solid tumor patient populations...
July 23, 2024: Journal of Oncology Pharmacy Practice
Maria Chiara Gelmi, Arnoud H de Ru, Peter A van Veelen, Rayman T N Tjokrodirijo, Marc-Henri Stern, Alexandre Houy, Robert M Verdijk, T H Khanh Vu, Bruce R Ksander, Jolanda Vaarwater, Emine Kilic, Erwin Brosens, Martine J Jager
PURPOSE: Cell lines are being used in preclinical uveal melanoma (UM) research. Because not all cell lines harbor typical GNAQ or GNA11 hotspot mutations, we aimed at better classifying them and determining whether we could find genetic causes to explain the protein and mRNA expression profiles of the cell lines. METHODS: We studied protein and mRNA expression of 14 UM cell lines and determined the presence of single nucleotide variants and small insertions and deletions with next-generation sequencing and copy number alterations with a single nucleotide polymorphism array...
July 1, 2024: Investigative Ophthalmology & Visual Science
Kimberly A Sable, Sarah A Korger, Yaohui G Xu, Daniel D Bennett, Molly A Hinshaw, Anne E Rosin
With the increasing utilization of telemedicine since the COVID-19 pandemic, it is critical that clinicians have an appropriate understanding of the application of virtual care resources, including teledermatology. We present a case series of 3 patients to demonstrate the clinical utility of teledermatology in reducing the time to diagnosis of various rare and/or aggressive cutaneous malignancies, including Merkel cell carcinoma, malignant melanoma, and atypical fibroxanthoma. Cases were obtained from one large Midwestern medical center during the month of July 2021...
May 2024: Cutis; Cutaneous Medicine for the Practitioner
Remco van Doorn
No abstract text is available yet for this article.
July 23, 2024: British Journal of Dermatology
Jorge Cuenca-Escalona, Johanna Bödder, Beatriz Subtil, Marta Sánchez-Sánchez, Marcos Vidal-Manrique, Mark W D Sweep, Jonathan A Fauerbach, Alessandra Cambi, Georgina Flórez-Grau, I Jolanda M de Vries
Tumor-derived prostaglandin E2 (PGE2) impairs anti-tumor immunity by priming suppressive functions on various immune cell types, including dendritic cells (DCs). In this way, tumors mediate DC dysfunction and hamper their anti-tumoral activity. PGE2 is known to modulate DC function via signaling through the E-prostanoid receptor type (EP) 2 and EP4. Preclinical studies have demonstrated the therapeutic value of targeting EP2/4 receptor signaling in DCs. Ongoing phase I clinical trials with EP antagonists have shown immunomodulation in cancer patients...
July 23, 2024: Journal of Leukocyte Biology
Mitchell A Taylor, Sierra I Thomas, Divya Sharma, Vanessa B Voss
No abstract text is available yet for this article.
July 23, 2024: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
Biswajit Basu, Ayon Dutta, Dipanjana Ash, Bhupendra Prajapati
Skin cancer, a global burden for particularly white people, is classified as various histopathological types, including malignant melanoma, basal and squamous cell carcinoma, on the basis of affected different skin layers. Clinical adjuvant therapy (electro-chemotherapy, radio- and immuno therapy), surgical techniques (Cryosurgery, laser treatment, dermabrasion, Moh's micrographic surgery), photodynamic treatment and theranostic approaches are confined only for the treatment of serious health issues. Therefore, nanotechnology based approaches, especially nanoemulsion, a non-spontaneous, transparent or translucent, kinetically stable nanostructured (1-1000nm) colloidal dispersion (comprised of oil, water and surfactant/cosurfactant), are being popularised as a potential topical nanocarrier to deliver BCS class II and IV anti-neoplastic drugs attributing to its capacity for both active and passive tumor targeting in controlled or sustained manner and improving bioavailability via enhancing permeabilityretention effect with minimal adverse effects...
July 22, 2024: Current Pharmaceutical Biotechnology
Jingping Wang, Yaping Wang, Xiaofang Jiang
Melanoma poses a challenge in oncology because of its aggressive nature and limited treatment modalities. The tumor microenvironment (TME) in melanoma contains unique properties such as an immunosuppressive and high-density environment, unusual vasculature, and a high number of stromal and immunosuppressive cells. In recent years, numerous experiments have focused on boosting the immune system to effectively remove malignant cells. Adjuvants, consisting of phytochemicals, toll-like receptor (TLR) agonists, and cytokines, have shown encouraging results in triggering antitumor immunity and augmenting the therapeutic effectiveness of anticancer therapy...
July 23, 2024: Journal of Drug Targeting
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.